United States v. Bel-Mar Laboratories, Inc.

284 F. Supp. 875, 1968 U.S. Dist. LEXIS 7793
CourtDistrict Court, E.D. New York
DecidedMay 20, 1968
Docket67-CR-378
StatusPublished
Cited by22 cases

This text of 284 F. Supp. 875 (United States v. Bel-Mar Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Bel-Mar Laboratories, Inc., 284 F. Supp. 875, 1968 U.S. Dist. LEXIS 7793 (E.D.N.Y. 1968).

Opinion

Memorandum of Decision and Order

MISHLER, District Judge.

Defendants have been charged under a fourteen count information with having *878 unlawfully introduced or delivered for introduction into interstate commerce various misbranded and adulterated injectable drugs in violation of section 331 (a) of title 21, United States Code. 1

The odd numbered counts of the information contain the allegations that the drugs were adulterated, while the charges of misbranding are set forth in the even numbered counts.

The government contends that all of the subject drugs were adulterated within the meaning of section 351(a) (2) (B) of title 21, in that “ * * * the methods used in, or the facilities or controls used for, * * * [their] manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such * * * [drugs meet] the requirements of this chapter as to safety and * * * [have] the identity and strength, and * * * [meet] the quality and purity characteristics, which * * * [they purport] or * * * [are] represented to possess * *

In addition, the government asserts that the drugs referred to in counts seven, nine and thirteen were also adulterated within the meaning of section 351(c), in that their strength differed from, or their purity or quality fell below, that which they purport or are represented to possess. 2

The misbránding charges are to the effect that certain allegedly false and misleading statements are contained in the labeling of the subject drugs. Counts two and four charge that certain statements on the ampule labels were inconsistent with statements on the carton labels. 3 Count four also complains that the labeling of the particular drug in question lacked adequate directions for the use of a prescription drug, and failed to bear any statement of the route of administration, as required by the regulations of the Food and Drug Administration. 4 In counts six, eight, ten and fourteen the alleged misstatements relate to the strengths and qualities of the various drugs. Finally, in count twelve the government maintains that the carton insert did not relate to the drug with which it was used, but rather to a different drug.

Defendants, in turn, have made the following set of motions: (1) a motion to dismiss various counts of the information, on several grounds, pursuant to Rule 12(b) of the Federal Rules of Criminal Procedure; (2) an application for the convening of a three-judge district court under section 2282 of title 28; (3) a motion for an order permitting defendants to obtain both copies of the government’s scientific analyses upon which this proceeding has been based, and representative samples of the allegedly objectionable printed material and drugs, pursuant to Rule 16(a) (2) of the Federal Rules and section 372(b) of title 21; (4) a motion for discovery and inspection of any statements made by defendants that are within the government’s possession, custody or control, and of various labels and carton inserts pertinent to the charges of misbranding, pursuant to Rule 16; and (5) a motion for a bill of particulars pursuant to Rule 7 (f).

*879 The motion to dismiss is directed against ten of the fourteen counts of the information, and is based upon several distinct theories, none of which is applicable to all of the challenged counts. First, defendants attack all of the odd numbered counts on the ground that section 351(a) (2) (B), which is the sole statutory predicate for four out of the seven odd numbered counts, is unconstitutional. More specifically, they argue that said section is devoid of any definite, certain or ascertainable standards with which one could determine whether the methods being used in, or the facilities or controls being used for the manufacture, processing, packing or holding of a particular drug conform to, or are being operated or administered in conformity with “current good manufacturing practice.” As a result, they contend, the section is too vague, indefinite and uncertain under the fifth amendment, and fails to inform defendants to the nature and cause of the charges based thereon, in violation of the sixth amendment.

Second, defendants assert that all of the odd numbered counts are defective in that they are merely couched in the language of the statute; they are vague, indefinite and uncertain; and they fail to charge or aver that defendants committed any acts constituting an offense under any federal statute.

Third, defendants also move to dismiss counts nine, ten, thirteen and fourteen on the ground that said counts fail to allege any facts to show that defendant’s drugs do not fall within the permissible variations or exemptions envisaged by section 352(b) of title 21. 5 And finally, defendants attack counts eight, ten and fourteen as duplicitous.

As a concomitant to their challenge to the constitutionality of section 351(a) (2) (B), defendants request the convening of a three-judge court for the stated purpose of securing a permanent injunction restraining the enforcement, operation or execution of said section as against them. 6 Injunctive relief is unnecessary in this case, however, since defendants have an adequate available legal remedy with which they may place the pertinent section’s constitutionality at issue and, thereby, attempt to prevent its use against them — their pending motion to dismiss the relevant counts of the information. The provision for the convening of a three-judge court and direct appeal to Supreme Court was never intended to apply to all situations where the validity of an act of Congress is drawn into question. See, Flemming v. Nestor, 363 U.S. 603, 607, 80 S.Ct. 1367, 1371, 4 L.Ed.2d 1435 (1960). Moreover, even assuming that a three-judge court might be called under similar circumstances, this court would still refuse to convene such a panel because, for the reasons hereinafter stated, defendants’ claim of unconstitutionality is insubstantial. See, Ex Parte Poresky, 290 U.S. 30, 54 S.Ct. 3, 78 L.Ed. 152 (1933); Utica Mut. Ins. Co. v. Vincent, 375 F.2d *880 129, 130 (2d Cir.), cert. denied, 389 U.S. 839, 88 S.Ct. 63, 19 L.Ed.2d 102 (1967).

It is well settled that a penal statute must fix an ascertainable standard of guilt, and must adequately inform the accused of the nature and cause of the charge against him. See, United States v. Wiesenfeld Warehouse Co., 376 U.S. 86, 84 S.Ct. 559, 11 L.Ed.2d 536 (1964); Boyce Motor Lines v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Grand Jury Subpoena
220 F.R.D. 130 (D. Massachusetts, 2004)
United States v. Green
144 F.R.D. 631 (W.D. New York, 1992)
United States v. 789 Cases, More or Less
799 F. Supp. 1275 (D. Puerto Rico, 1992)
United States v. Pamela Mejia Armenta Iglesias
881 F.2d 1519 (Ninth Circuit, 1989)
United States v. Moyer
713 F. Supp. 1035 (N.D. Ohio, 1989)
United States v. Beech-Nut Nutrition Corp.
659 F. Supp. 1487 (E.D. New York, 1987)
United States v. Feola
651 F. Supp. 1068 (S.D. New York, 1987)
United States v. Western Serum Co., Inc.
498 F. Supp. 863 (D. Arizona, 1980)
Pueblo v. Andreu González
105 P.R. Dec. 315 (Supreme Court of Puerto Rico, 1976)
United States v. Medwick Laboratories, Inc.
416 F. Supp. 832 (N.D. Illinois, 1976)
United States v. Article of Drug
484 F.2d 748 (Seventh Circuit, 1973)
United States v. Dianovin Pharmaceuticals, Inc.
342 F. Supp. 724 (D. Puerto Rico, 1972)
United States v. Lit Drug Company
333 F. Supp. 990 (D. New Jersey, 1971)

Cite This Page — Counsel Stack

Bluebook (online)
284 F. Supp. 875, 1968 U.S. Dist. LEXIS 7793, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-bel-mar-laboratories-inc-nyed-1968.